| 000 | 03328nam a22003857a 4500 | ||
|---|---|---|---|
| 008 | 240807s20242024 xxu||||| |||| 00| 0 eng d | ||
| 022 | _a0277-2116 | ||
| 040 | _aOvid MEDLINE(R) | ||
| 099 | _a38828781 | ||
| 245 | _aEvaluation of pediatric patients for intestinal transplantation in the modern era. | ||
| 251 | _aJournal of Pediatric Gastroenterology & Nutrition. 2024 Jun 03 | ||
| 252 | _aJ Pediatr Gastroenterol Nutr. 2024 Jun 03 | ||
| 253 | _aJournal of pediatric gastroenterology and nutrition | ||
| 260 | _c2024 | ||
| 260 | _fFY2024 | ||
| 260 | _p2024 Jun 03 | ||
| 265 | _saheadofprint | ||
| 265 | _tPublisher | ||
| 266 | _d2024-08-07 | ||
| 266 | _z2024/06/03 06:33 | ||
| 520 | _aCONCLUSIONS: Despite recent improvements in IF management, IFALD remains a prominent reason for ITx referral. Complications of IF inherent to ITx candidacy influence postevaluation and post-ITx survival. Copyright © 2024 European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. | ||
| 520 | _aMETHODS: Retrospective chart review of 97 patients evaluated for ITx from January 2014 to December 2021 including data from referring institutions and protocol laboratory testing, body imaging, endoscopy, and liver biopsy in selected cases. Survival analysis used Kaplan-Meier estimates and Cox proportional hazards regression. | ||
| 520 | _aOBJECTIVES: To review recent evaluations of pediatric patients with intestinal failure (IF) for intestinal transplantation (ITx), waiting list decisions, and outcomes of patients listed and not listed for ITx at our center. | ||
| 520 | _aRESULTS: Patients were referred almost entirely from outside institutions, one-third because of intestinal failure-associated liver disease (IFALD), two-thirds because of repeated infective and non-IFALD complications under minimally successful intestinal rehabilitation, and a single patient because of lost central vein access. The majority had short bowel syndrome (SBS). Waiting list placement was offered to 67 (69%) patients, 40 of whom for IFALD. The IFALD group was generally younger and more likely to have SBS, have received more parenteral nutrition, have demonstrated more evidence of chronic inflammation and have inferior kidney function compared to those offered ITx for non-IFALD complications and those not listed. ITx was performed in 53 patients. Superior postevaluation survival was independently associated with higher serum creatinine (hazard ratio [HR] 15.410, p = 014), whereas inferior postevaluation survival was associated with ITx (HR 0.515, p = 0.035) and higher serum fibrinogen (HR 0.994, p = 0.005). | ||
| 546 | _aEnglish | ||
| 650 | _aIN PROCESS -- NOT YET INDEXED | ||
| 650 | _zAutomated | ||
| 656 | _aMedStar Georgetown University Hospital/MedStar Washington Hospital Center | ||
| 656 | _aPediatrics Residency | ||
| 657 | _aJournal Article | ||
| 700 |
_aOzler, Oguz _bMGUH _cPediatrics Residency _dMD |
||
| 790 | _aBryan NS, Russell SC, Ozler O, Sugiguchi F, Yazigi NA, Khan KM, Ekong UD, Vitola BE, Guerra JF, Kroemer A, Fishbein TM, Matsumoto CS, Ghobrial SS, Kaufman SS | ||
| 856 |
_uhttps://dx.doi.org/10.1002/jpn3.12274 _zhttps://dx.doi.org/10.1002/jpn3.12274 |
||
| 942 |
_cART _dArticle |
||
| 999 |
_c14407 _d14407 |
||